Zobrazeno 1 - 10
of 80
pro vyhledávání: '"Claus Lattrich"'
Publikováno v:
Der Gynäkologe. 48:581-585
Hintergrund Die Hormontherapie (HT) in der Peri- und Postmenopause ist eine sehr haufig verordnete Pharmakotherapie.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f09734bba34c1a5dfba6b7e6a2c5c319
https://doi.org/10.1007/s00129-015-3729-5
https://doi.org/10.1007/s00129-015-3729-5
Autor:
Claus Lattrich, Olaf Ortmann
Publikováno v:
Frauenheilkunde up2date. 8:327-338
Hormone Therapy in Periand Postmenopausal Women. Hormone therapy (HT) in periand postmenopausal women is one of the most commonly prescribed pharmacotherapies. HT should be used only in the presence of a clear indication for the purposes described in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ebabe4a84e1d686ece21313bef84afea
https://doi.org/10.1055/s-0033-1358001
https://doi.org/10.1055/s-0033-1358001
Publikováno v:
Frauenheilkunde up2date. 8:315-326
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dddc871078a63361f645d1f1dc9fd591
https://doi.org/10.1055/s-0033-1346897
https://doi.org/10.1055/s-0033-1346897
Publikováno v:
Maturitas. 77:336-343
Objective Local application of estradiol (E2) to treat vulvovaginal atrophy in postmenopausal breast cancer patients receiving aromatase inhibitors is known to elevate serum estradiol levels and thereby might counteract breast cancer therapy. Thus, v
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38bb8e69de1722a40dd3ad2424a3a0ea
https://doi.org/10.1016/j.maturitas.2014.01.004
https://doi.org/10.1016/j.maturitas.2014.01.004
Publikováno v:
Der Gynäkologe. 47:9-12
Uterusmyome sind gutartige, hormonsensitive Tumoren. Sie sind die haufigsten pelvinen Tumoren der Frau und in der Regel asymptomatisch. Die wichtigsten Symptome bei einem Uterus myomatosus sind Blutungsstorungen, Drucksymptomatik und reproduktive Dys
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4f43fd00176cd35cd80846418607384c
https://doi.org/10.1007/s00129-013-3199-6
https://doi.org/10.1007/s00129-013-3199-6
Publikováno v:
Frauenheilkunde up2date. 7:375-385
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fdbc1fa51028d5eca7b10f84ff973263
https://doi.org/10.1055/s-0033-1346683
https://doi.org/10.1055/s-0033-1346683
Publikováno v:
Frauenheilkunde up2date. 7:43-54
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::afbd9c62511d56a888354cb5b5241a43
https://doi.org/10.1055/s-0032-1324940
https://doi.org/10.1055/s-0032-1324940
Publikováno v:
Steroids. 78:195-202
Expression of estrogen receptor β (ERβ) has been described to reduce growth of cancer cell lines derived from hormone-dependent tumors, like breast cancer. In this study we tested to what extent two ERβ agonists, androgen derivative 3β-Adiol and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee9d307b0650d4507f5c149801f2cddf
https://doi.org/10.1016/j.steroids.2012.10.014
https://doi.org/10.1016/j.steroids.2012.10.014
Publikováno v:
Gynecologic Oncology. 127:673-676
Estrogen receptor β is expressed in normal and neoplastic ovarian and endometrial tissues. Recent studies indicate that levels of this receptor decline in ovarian tumorigenesis, like in breast or prostate cancer. Furthermore, ERβ expression has bee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::321859222b4d581aac0238b90fa89e13
https://doi.org/10.1016/j.ygyno.2012.09.006
https://doi.org/10.1016/j.ygyno.2012.09.006
Publikováno v:
Geburtshilfe und Frauenheilkunde. 76
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d7b4b84af13b5f97fc84ac61fd659784
https://doi.org/10.1055/s-0036-1580667
https://doi.org/10.1055/s-0036-1580667